Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 11/20 | 0.68 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.56 |
| ▸ | TACR2 | P21452 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448648 | 0.81 | TACR3 (1.00) | TACR3PTGER4TACR2CYP3A4KDM4E | |
| SCHEMBL14133006 | 0.78 | TACR3 (0.72) | TACR3PTGER4TACR2CYP3A4KDM4E | |
| SCHEMBL7684672 | 0.77 | TACR3 (0.74) | TACR3PTGER4TACR2CYP3A4KDM4E | |
| SCHEMBL7684676 | 0.77 | TACR3 (0.74) | TACR3PTGER4TACR2CYP3A4KDM4E | |
| SCHEMBL14623959 | 0.75 | TACR3 (0.72) | TACR3PTGER4TACR2CYP3A4KDM4E | |
| SCHEMBL14582371 | 0.75 | TACR3 (0.72) | TACR3CYP3A4KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6969107 | 0.74 | TACR3 (0.71) | TACR3PTGER4TACR2CYP3A4KDM4E | |
| SCHEMBL5049690 | 0.74 | TACR3 (0.70) | TACR3PTGER4TACR2CYP3A4KDM4E | |
| SCHEMBL8617743 | 0.73 | CYP3A4 (0.65) | TACR3PTGER4CYP3A4KDM4EMEN1 | |
| SCHEMBL29586433 | 0.73 | LMNA (0.76) | TACR3CYP3A4KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624175-B2 | 4-heterocyclic substituted quinoline derivative treats disorderes associated with pathogenic neurokinin-3 receptor, such as anxiety, depression, schizophrenia, obesity, chronic pulmonary obstructive disorder or pain | NEUROGEN CORPORATION | 2003-09-23 | — | — | US | disclosed |
| EP-1165542-B1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20020198232-A1 | 4-substituted quinoline derivatives | NEUROGEN CORPORATION (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2000058303-A9 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6413982-B1 | 5-ETHYL-5-PHENYL-2-(3-METHOXY-2-PHENYLQUINOLIN-4-YL)-IMIDAZO -LINE; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISEASES AND DISORDERS; BINDS WITH HIGH AFFINITY TO NEUROKININ-3 (NK-3) AND/OR GAMMA-AMINOBUTYRIC ACID RECEPTORS; SYNERGISTIC | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
| EP-1165542-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058303-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198232-A1 | 4-substituted quinoline derivatives | GABRA3, GABRB3, GABRR3 | TACR3 42/4885PTGER4 1186/4885TACR2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.